The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! About 414,321 shares traded hands. Agenus Inc (NASDAQ:AGEN) has risen 59.24% since March 15, 2016 and is uptrending. It has outperformed by 53.75% the S&P500.
The move comes after 7 months positive chart setup for the $518.84 million company. It was reported on Oct, 18 by Barchart.com. We have $8.38 PT which if reached, will make NASDAQ:AGEN worth $202.35M more.
Analysts await Agenus Inc (NASDAQ:AGEN) to report earnings on October, 25. They expect $-0.30 EPS, down 87.50% or $0.14 from last year’s $-0.16 per share. After $-0.24 actual EPS reported by Agenus Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Agenus Inc (NASDAQ:AGEN) Ratings Coverage
Out of 4 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Agenus has been the topic of 6 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. The rating was initiated by Jefferies with “Buy” on Wednesday, December 16. Maxim Group upgraded the stock to “Buy” rating in Friday, March 11 report. The firm earned “Buy” rating on Friday, July 29 by Jefferies. The firm earned “Hold” rating on Tuesday, October 27 by Maxim Group. MLV maintained the stock with “Buy” rating in Monday, July 27 report.
According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in Q2 2016. Its down 0.58, from 1.38 in 2016Q1. The ratio turned negative, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
The Massachusetts-based Rhumbline Advisers has invested 0% in Agenus Inc (NASDAQ:AGEN). Sei Investments Com has 2,666 shares for 0% of their US portfolio. The Washington-based Fisher Asset Mngmt Limited Liability has invested 0% in Agenus Inc (NASDAQ:AGEN). Ingalls & Snyder Ltd Liability Corporation, a New York-based fund reported 252,300 shares. Moreover, Legal General Gru Inc Public Limited Liability has 0% invested in Agenus Inc (NASDAQ:AGEN) for 9,915 shares. Schwab Charles Mngmt has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Oracle Invest Mgmt holds 1.75% of its portfolio in Agenus Inc (NASDAQ:AGEN) for 1.86M shares. Fmr Llc, a Massachusetts-based fund reported 2.59M shares. First Allied Advisory Incorporated has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Qvt Financial Ltd Partnership reported 3.68M shares or 1.03% of all its holdings. Finemark Bank And Tru has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Citigroup Inc, a New York-based fund reported 16,651 shares. Northern Tru has 812,853 shares for 0% of their US portfolio. Trellus Mgmt Limited Liability Company reported 122,500 shares or 0.81% of all its holdings. Teachers Advsr Inc has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN).
Insider Transactions: Since May 5, 2016, the stock had 3 insider purchases, and 0 sales for $513,570 net activity. $6,975 worth of Agenus Inc (NASDAQ:AGEN) was bought by Baysal Ozer. WIINBERG ULF bought 30,000 shares worth $188,700. 100,000 Agenus Inc (NASDAQ:AGEN) shares with value of $317,895 were bought by ARMEN GARO H.
AGEN Company Profile
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.